Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 23149693)

1.

Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.

Scherpenisse M, Mollers M, Schepp RM, Meijer CJ, de Melker HE, Berbers GA, van der Klis FR.

Hum Vaccin Immunother. 2013 Feb;9(2):314-21. Epub 2012 Nov 13.

2.

Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine.

Schwarz TF, Kocken M, Petäjä T, Einstein MH, Spaczynski M, Louwers JA, Pedersen C, Levin M, Zahaf T, Poncelet S, Hardt K, Descamps D, Dubin G.

Hum Vaccin. 2010 Dec;6(12):1054-61. Epub 2010 Dec 1.

3.

Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.

Petäjä T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, Lehtinen M, Descamps D.

Int J Cancer. 2011 Nov 1;129(9):2147-57. doi: 10.1002/ijc.25887. Epub 2011 Mar 11.

PMID:
21190190
4.

Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.

Barzon L, Squarzon L, Masiero S, Pacenti M, Marcati G, Mantelli B, Gabrielli L, Pascucci MG, Lazzarotto T, Caputo A, Palù G.

Vaccine. 2014 Sep 15;32(41):5357-62. doi: 10.1016/j.vaccine.2014.07.014. Epub 2014 Jul 18.

PMID:
25045814
5.

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.

Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S.

PLoS One. 2013 May 1;8(5):e61825. doi: 10.1371/journal.pone.0061825. Print 2013.

6.

Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.

Scherpenisse M, Schepp RM, Mollers M, Meijer CJ, Berbers GA, van der Klis FR.

PLoS One. 2013 Sep 18;8(9):e74797. doi: 10.1371/journal.pone.0074797. eCollection 2013.

7.

Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.

Bissett SL, Draper E, Myers RE, Godi A, Beddows S.

Vaccine. 2014 Feb 26;32(10):1139-46. doi: 10.1016/j.vaccine.2014.01.008. Epub 2014 Jan 15.

8.

Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.

LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, Cover J, Pinto LA, Safaeian M.

Vaccine. 2014 Oct 29;32(47):6303-11. doi: 10.1016/j.vaccine.2014.08.071. Epub 2014 Sep 16.

PMID:
25218297
9.

The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.

Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M, Radley D, Vuocolo S, Garner EI, Haupt RM, Bryan JT.

Hum Vaccin. 2011 Feb;7(2):230-8. Epub 2011 Feb 1.

10.

Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.

Brown D, Müller M, Sehr P, Pawlita M, Seitz H, Rubio I, Antonello J, Radley D, Roberts C, Saah A.

Vaccine. 2014 Oct 7;32(44):5880-7. doi: 10.1016/j.vaccine.2014.08.004. Epub 2014 Aug 19.

PMID:
25148777
11.

Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study.

Namujju PB, Pajunen E, Simen-Kapeu A, Hedman L, Merikukka M, Surcel HM, Kirnbauer R, Apter D, Paavonen J, Hedman K, Lehtinen M.

BMC Res Notes. 2014 Jul 11;7:445. doi: 10.1186/1756-0500-7-445.

12.

Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.

Nardelli-Haefliger D, Lurati F, Wirthner D, Spertini F, Schiller JT, Lowy DR, Ponci F, De Grandi P.

Vaccine. 2005 May 25;23(28):3634-41.

PMID:
15882523
13.

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P.

J Natl Cancer Inst. 2003 Aug 6;95(15):1128-37.

14.

A human papillomavirus type 16 vaccine by oral delivery of L1 protein.

Sasagawa T, Tani M, Basha W, Rose RC, Tohda H, Giga-Hama Y, Azar KK, Yasuda H, Sakai A, Inoue M.

Virus Res. 2005 Jun;110(1-2):81-90.

PMID:
15845258
15.

Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice.

Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, Park JS, Poo H.

Vaccine. 2012 May 9;30(22):3286-94. doi: 10.1016/j.vaccine.2012.03.009. Epub 2012 Mar 15.

PMID:
22426329
16.

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.

Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.

Hum Vaccin Immunother. 2013 Jul;9(7):1399-406. doi: 10.4161/hv.24340. Epub 2013 Apr 9.

17.

Plasmablast-derived polyclonal antibody response after influenza vaccination.

He XS, Sasaki S, Narvaez CF, Zhang C, Liu H, Woo JC, Kemble GW, Dekker CL, Davis MM, Greenberg HB.

J Immunol Methods. 2011 Feb 28;365(1-2):67-75. doi: 10.1016/j.jim.2010.12.008. Epub 2010 Dec 21.

18.

Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.

Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, Berbers GA, van der Klis FR, Wulffraat NM.

Ann Rheum Dis. 2014 Aug;73(8):1500-7. doi: 10.1136/annrheumdis-2013-203429. Epub 2013 May 30.

PMID:
23723319
19.

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.

Kemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, Giannini SL, Rodriguez AC, Porras C, Herrero R, Hildesheim A, Pinto LA; Costa Rica Vaccine Trial (CVT) Group.

Vaccine. 2008 Jul 4;26(29-30):3608-16. doi: 10.1016/j.vaccine.2008.04.074. Epub 2008 May 19.

20.

Transgenic tobacco expressed HPV16-L1 and LT-B combined immunization induces strong mucosal and systemic immune responses in mice.

Hongli L, Xukui L, Ting L, Wensheng L, Lusheng S, Jin Z.

Hum Vaccin Immunother. 2013 Jan;9(1):83-9. doi: 10.4161/hv.22292. Epub 2012 Oct 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk